Medical Devices comparable sales growth measures year-over-year growth in Abbott's Medical Devices segment after the company's specified comparability adjustments.
Abbott reported 8.4% Medical Devices comparable sales growth in the second quarter of 2026.
Comparable growth is narrower than reported growth
Reported Medical Devices sales increased 9.0%, while comparable growth was 8.4%.
The comparable measure removes specified acquisition, divestiture, and foreign-exchange effects so investors can separate portfolio activity from those items.
Franchise mix explains the segment result
Electrophysiology led the portfolio, while Neuromodulation grew much more slowly.
Read it with Electrophysiology comparable growth and Diabetes Care comparable growth.
Primary source: Abbott Q2 2026 earnings release filed with the SEC.
Part of the Medical Device Portfolio Growth
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthPortfolio and geographic growth2 of 2 bridge concepts supportedContinue through this bridge:U.S. vs. International Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare medical device portfolio growth
Compare Abbott Medical Devices growth after specified acquisition, divestiture and FX adjustments.
Explore more topics in the Financial Research Encyclopedia.